CHICAGO, Sept. 1, 2011 /PRNewswire/ -- The Female Health Company (NASDAQ-CM: FHCO), which manufactures and markets the FC2 Female Condom®, today announced that the Company's CEO, O.B. Parrish, and its CFO, Donna Felch, are scheduled to make a presentation at Rodman & Renshaw's Global Investment Conference at 4:05 p.m. on Tuesday, September 13, 2011, in the Empire Room (lobby level).
The Conference will be held September 11-13, 2011 at the New York Waldorf-Astoria in New York City. Additional information on the Conference is available on the Internet at www.rodmanandrenshaw.com.
About Rodman & Renshaw
Rodman & Renshaw is a full-service investment banking firm that is dedicated to providing investment banking services to companies that have significant recurring capital needs due to their growth and development strategies. The firm also provides research, sales and trading services to institutional investor clients that focus on such companies.
Through its life sciences investment banking team, Rodman & Renshaw provides a broad range of investment banking services to biotechnology, specialty pharmaceutical, medical device and other companies operating in the life science space. The team consists of seasoned professionals, many of whom have PhDs or other advanced medical or scientific degrees. Their experience and expertise enable the firm to deliver the specialized advice and differentiated services its clients demand.
Additional information on Rodman & Renshaw is available on the Internet at www.rodmanandrenshaw.com.
About The Female Health Company
The Female Health Company, based in Chicago, Illinois, manufactures and markets the FC2 Female Condom® (FC2), which is available in the U.S. and approximately 120 other countries around the world. The Company owns certain worldwide rights to the FC2 Female Condom®, including patents that have been issued in the U.S., Europe, Canada, Australia, South Africa, Japan, China, Spain, Mexico, Greece and Turkey and are pending in various countries. The FC2 Female Condom® is the only available FDA-approved product controlled by a woman that offers dual protection against sexually transmitted diseases, including HIV/AIDS, and unintended pregnancy. The World Health Organization (WHO) has cleared FC2 for purchase by U.N. agencies.
"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:
The statements in this release which are not historical facts are forward-looking statements based upon the Company's current plans and strategies, and reflect the Company's current assessment of the risks and uncertainties related to its business, including such things as product demand and market acceptance; the economic and business environment and the impact of government pressures; currency risks; capacity; efficiency and supply constraints; and other risks detailed in the Company's press releases, shareholder communications and Securities and Exchanges Commission filings. Actual events affecting the Company and the impact of such events on the Company's operations may vary from this currently anticipated.
For more information about the Female Health Company visit the Company's website at http://www.femalehealth.com and http://www.femalecondom.org. If you would like to be added to the Company's e-mail alert list, please send an e-mail to FHCInvestor@femalehealthcompany.com.
SOURCE The Female Health Company